Log in

NASDAQ:SYNH - Syneos Health Stock Price, Forecast & News

$70.82
-0.68 (-0.95 %)
(As of 02/23/2020 03:51 PM ET)
Today's Range
$69.50
Now: $70.82
$72.12
50-Day Range
$59.04
MA: $62.95
$71.50
52-Week Range
$36.72
Now: $70.82
$72.44
Volume606,234 shs
Average Volume334,244 shs
Market Capitalization$7.35 billion
P/E Ratio57.11
Dividend YieldN/A
Beta1.48
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYNH
CUSIPN/A
Phone919-876-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.68 billion
Cash Flow$5.15 per share
Book Value$29.19 per share

Profitability

Net Income$24.28 million

Miscellaneous

Employees24,000
Market Cap$7.35 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for SYNH and its competitors with MarketBeat's FREE daily newsletter.


Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

How were Syneos Health's earnings last quarter?

Syneos Health Inc (NASDAQ:SYNH) announced its earnings results on Thursday, February, 20th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.01 by $0.02. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. Syneos Health had a return on equity of 10.12% and a net margin of 2.81%. The company's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.95 earnings per share. View Syneos Health's Earnings History.

When is Syneos Health's next earnings date?

Syneos Health is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Syneos Health.

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health issued an update on its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of $3.58-3.78 for the period, compared to the Thomson Reuters consensus estimate of $3.65. The company issued revenue guidance of $4.88-5.00 billion, compared to the consensus revenue estimate of $4.94 billion.

What price target have analysts set for SYNH?

11 brokers have issued 1 year price objectives for Syneos Health's stock. Their forecasts range from $48.00 to $82.00. On average, they expect Syneos Health's share price to reach $69.11 in the next twelve months. This suggests that the stock has a possible downside of 2.4%. View Analyst Price Targets for Syneos Health.

What is the consensus analysts' recommendation for Syneos Health?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.

Has Syneos Health been receiving favorable news coverage?

Media stories about SYNH stock have been trending negative on Sunday, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syneos Health earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Syneos Health.

Who are some of Syneos Health's key competitors?

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include AT&T (T), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Icon (ICLR), Jazz Pharmaceuticals (JAZZ), Netflix (NFLX), Skyworks Solutions (SWKS), Alibaba Group (BABA) and Iqvia (IQV).

Who are Syneos Health's key executives?

Syneos Health's management team includes the folowing people:
  • Mr. Alistair Macdonald, CEO & Director (Age 49)
  • Mr. Jason M. Meggs, Chief Financial Officer (Age 43)
  • Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 43)
  • Mr. Michael Adam Bell, Consultant (Age 63)
  • Mr. Robert Parks, Exec. VP & Chief Accounting Officer

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (2.23%), State Street Corp (1.92%), Bank of New York Mellon Corp (1.51%), Goldman Sachs Group Inc. (1.44%), Boston Partners (1.25%) and GW&K Investment Management LLC (1.05%). Company insiders that own Syneos Health stock include Alistair Macdonald, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.

Which major investors are selling Syneos Health stock?

SYNH stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Principal Financial Group Inc., Prudential Financial Inc., Sei Investments Co., AXA, Goldman Sachs Group Inc., Boston Partners and Rothschild & Co. Asset Management US Inc.. View Insider Buying and Selling for Syneos Health.

Which major investors are buying Syneos Health stock?

SYNH stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Jennison Associates LLC, Hennessy Advisors Inc., Barclays PLC, Knights of Columbus Asset Advisors LLC, Hawk Ridge Capital Management LP, ArrowMark Colorado Holdings LLC and Magnetar Financial LLC. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $70.82.

How big of a company is Syneos Health?

Syneos Health has a market capitalization of $7.35 billion and generates $4.68 billion in revenue each year. The company earns $24.28 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.View Additional Information About Syneos Health.

What is Syneos Health's official website?

The official website for Syneos Health is http://www.syneoshealth.com/.

How can I contact Syneos Health?

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]


MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  500 (Vote Outperform)
Underperform Votes:  402 (Vote Underperform)
Total Votes:  902
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel